Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR)...
14 KB (1,135 words) - 21:03, 12 July 2024
mutations and fail standard platinum based chemotherapy erdafitinib can be used. Erdafitinib has shown a response rate of 40% in these patients. Five...
130 KB (12,788 words) - 05:06, 8 July 2024
Duvelisib Idelalisib Parsaclisib Cabozantinib Capmatinib Entrectinib Erdafitinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib...
12 KB (760 words) - 05:52, 10 June 2024
2018. "Janssen announces U.S. FDA breakthrough therapy designation for erdafitinib in the Treatment of metastatic urothelial cancer". Johnson and Johnson...
23 KB (742 words) - 04:57, 30 December 2023
The molecular formula C25H30N6O2 may refer to: Dalpiciclib Erdafitinib This set index page lists chemical structure articles associated with the same...
519 bytes (44 words) - 08:02, 16 April 2024
approval in the US and EU in 2017 for the treatment of breast cancer. Erdafitinib (brand name “Balversa”) is an FGFR inhibitor that was discovered with...
11 KB (1,050 words) - 13:29, 17 June 2024
Therapeutics postpartum depression Palbociclib Pfizer metastatic breast cancer Erdafitinib Janssen urothelial carcinoma Pembrolizumab Merck Sharp & Dohme advanced...
34 KB (180 words) - 22:09, 8 April 2024
Copanlisib L01EM03 Alpelisib L01EM04 Duvelisib L01EM05 Parsaclisib L01EN01 Erdafitinib L01EN02 Pemigatinib L01EN03 Infigratinib L01EN04 Futibatinib L01EX01...
12 KB (877 words) - 15:36, 25 January 2024
Duvelisib Idelalisib Parsaclisib Cabozantinib Capmatinib Entrectinib Erdafitinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib...
12 KB (758 words) - 23:46, 14 March 2024
of three launched drugs: ribociclib (Astex-Novartis collaboration), erdafitinib (Astex-Janssen collaboration) as well as the anaesthetic reversal agent...
7 KB (517 words) - 09:46, 7 April 2024